In Vitro and In Vivo Investigation of a Dual-Targeted Nanoemulsion Gel for the Amelioration of Psoriasis
Key Findings
- Nanoemulsion gel combining Thymoquinone (TQ) and Fulvic Acid (FA) developed for psoriasis treatment
- Molecular docking showed TQ and FA binding to IL-6 (4CNI) and TNF-α (6RMJ) targets
- FA incorporated at 100 mg/cm² in gel formulation as one of six treatment groups
- IMQ-induced psoriasis model in BALB/c mice — FA+TQ nanoemulsion reduced ear thickness, erythema, scaling
- PASI scoring system used: 0-4 scale for erythema, scaling, lesions, thickness
- TQ suppresses epidermal proliferation and differentiation via inhibiting dendritic cells and IL-6/TNF-α generation
Open-access study published in Gels (2023) developing a nanoemulsion gel combining thymoquinone (TQ, from Nigella sativa) and fulvic acid (FA) for psoriasis treatment. Both in vitro and in vivo (mouse model) experiments were conducted, along with molecular docking simulation to predict how FA and TQ interact with known psoriasis drug targets.
Study Design
The IMQ-induced psoriasis model in BALB/c mice is the standard animal model for psoriasis drug testing: imiquimod (IMQ) cream is applied to mouse skin to trigger psoriasis-like plaques, which are then treated with different formulations and measured using PASI scoring (0–4 scale for erythema, scaling, lesions, and skin thickness). Six groups were evaluated, including an FA-only gel group, a TQ-only group, and the combined TQ+FA nanoemulsion gel.
Molecular Docking Findings
In silico molecular docking showed both TQ and FA binding to IL-6 (target: 4CNI) and TNF-α (target: 6RMJ) — two of the central pro-inflammatory cytokines in psoriasis pathology. This confirms FA’s molecular-level interaction with the same targets that biological psoriasis drugs (adalimumab, tocilizumab) address, though at different binding sites and with different potency profiles.
FA’s Specific Contribution
The FA-only arm of the study showed measurable anti-psoriatic activity. However, the combined TQ+FA nanoemulsion outperformed both single-agent groups, making it difficult to quantify FA’s independent contribution to the observed benefit. What the study clearly establishes is that FA has a psoriasis-relevant mechanism (cytokine binding) and produces measurable anti-inflammatory effects in a validated psoriasis model. This is the most specific formulation study of FA for psoriasis in the knowledge graph.